Ananda Developments PLC Launch of CBD Whitepaper

RNS Number : 0428C

Ananda Developments PLC

29 August 2024

 

 

ANANDA DEVELOPMENTS PLC

("Ananda" or the "Company")

 

An introduction to Cannabidiol (CBD) as a Pharmaceutical Medicine: Ananda releases whitepaper on CBD Therapeutic Potential

 

Ananda Developments plc (AQSE: ANA), a life sciences company focused on the research and development of CBD-based therapies for a range of complex inflammatory pain conditions, has today released a whitepaper entitled 'An introduction to Cannabidiol (CBD) as a Pharmaceutical Medicine'.

 

The report provides a comprehensive overview of CBD's potential therapeutic reach. Despite a growing body of anecdotal evidence and preclinical research, there remains a critical gap in robust clinical data to fully understand CBD's efficacy and safety for various medical conditions.

 

The whitepaper examines the historical use of cannabis as a medicine, providing a foundation for understanding the compound's potential. It goes on to further consider the complex biological mechanisms underlying CBD's effects, including, but not limited to, its interactions with the endocannabinoid system and other key physiological pathways.

 

The report also presents a detailed overview of the current state of knowledge regarding CBD's potential benefits in various disease areas, such as chronic pain, autoimmune disorders, and neurodegenerative conditions. By highlighting the gaps in current research, the report emphasises the need for further clinical investigation to unlock CBD's full therapeutic potential.

 

Key takeaways from the report include:

·    CBD interacts with a wide range of targets in the body, potentially impacting numerous conditions.

·    CBD exhibits various therapeutic properties, including anti-inflammatory, analgesic, anticonvulsant, and anxiolytic effects.

·    Existing evidence supports the potential benefits of CBD in treating a wide range of conditions, including chronic pain, various autoimmune diseases, and certain cancers.

·    More clinical trials are needed to confirm CBD's efficacy for various conditions and determine optimal formulations, dosages, and administration methods.

This resource is designed as a guide for healthcare professionals, researchers, investors and organisations wanting to understand more about the potential of the CBD molecule, the work that is being done and still needs to be done to better understand its efficacy.

 

Melissa Sturgess, Ananda CEO commented: "Ananda Developments is at the forefront of exploring the therapeutic potential of CBD-based medicines. This report highlights the vast potential of this fascinating molecule and underscores the need for further clinical research to bring this potential to fruition and offer new treatment options for patients with a variety of conditions."

 

Download the report here: https://investors.anandadevelopments.com/activity-updates/an-introduction-to-cbd

 

To stay up to date with the latest developments at Ananda, we encourage you to follow our social media channels which are:  

·      Register at our Investor Hub: https://investors.anandadevelopments.com/s/a66906

·      Instagram: https://instagram.com/anandadevelopments?igshid=YmMyMTA2M2Y=   

·      LinkedIn: https://www.linkedin.com/company/anadevelopments/   

·      Twitter: https://twitter.com/AnandaPlc

·      Investor Meet Company: https://www.investormeetcompany.com/ananda-developments-plc/register-investor

 

-Ends-

 

The Directors of the Company accept responsibility for the contents of this announcement.

 

For more information please contact:

InvestorHub Engage with us directly at Ananda Developments Investor Hub	Sign up at https://investors.anandadevelopments.com/s/a66906
ANANDA DEVELOPMENTS PLC Chief Executive Officer Melissa Sturgess Finance Director Jeremy Sturgess-Smith	[phone] [e-mail]
SP ANGEL CORPORATE FINANCE LLP Corporate Finance Richard Morrison Caroline Rowe	[phone]
Corporate Broking Abigail Wayne Rob Rees
Yellow Jersey PR Charles Goodwin Zara McKinlay	[phone]

About Ananda Developments

Ananda is an AQSE-listed company whose ambition is to be a leading provider of cannabinoid-based medicines for the treatment of complex, chronic inflammatory pain conditions.

For further information on the Company visit https://anandadevelopments.com/ or sign up at https://investors.anandadevelopments.com/s/a66906.

https://investors.anandadevelopments.com/link/lyaw2r

 

 

 

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRASEMFLAELSELA